Klebsiella

Klebsiella: A Comprehensive Guide to Understanding This Gut Bacteria and Its Impact on Health

What is Klebsiella?

Klebsiella is a genus of gram-negative bacteria belonging to the Enterobacteriaceae family, which also includes Salmonella and E. coli. The most clinically significant species are Klebsiella pneumoniae, Klebsiella oxytoca, and Klebsiella granulomatis. While Klebsiella can be a normal resident of the human gut microbiome in small amounts, it can become an opportunistic pathogen when conditions allow it to overgrow.

These rod-shaped bacteria naturally colonise various parts of the human body, including the nasal passages, mouth, skin, and gastrointestinal tract. In healthy individuals with balanced gut flora, Klebsiella helps digest complex carbohydrates including lactose, resistant starches, inulin, fructose, and mannose. However, when the delicate balance of the microbiome is disrupted, Klebsiella can proliferate and cause significant health problems.

Understanding Gram-Negative Bacteria

As a gram-negative bacterium, Klebsiella possesses a unique outer membrane containing lipopolysaccharide (LPS), also known as endotoxin. This LPS is composed of three parts: lipid A (the most bioactive component), core oligosaccharides, and O-antigen polysaccharides. In Klebsiella pneumoniae, the LPS is present beneath a capsular layer, which provides additional protection.

The lipid A component of LPS is responsible for triggering powerful inflammatory responses in the human body through activation of Toll-like receptor 4 (TLR4). When bacterial cells divide, die, or are destroyed by the immune system, LPS is released into circulation, potentially causing fever, inflammation, and in severe cases, septic shock.

Klebsiella Pneumoniae: The Primary Pathogenic Species

Klebsiella pneumoniae is the most medically important species within the Klebsiella genus and has earned the concerning title of a “superbug” due to increasing antibiotic resistance. This bacterium can cause a wide range of infections, from respiratory tract infections to bloodstream infections, urinary tract infections, and gut-related conditions.

What Makes Klebsiella Pneumoniae So Resilient?

Several factors contribute to the persistence and difficulty in eradicating Klebsiella pneumoniae:

1. Biofilm Formation: Klebsiella forms protective biofilms that shield it from both the immune system and antibiotics, making treatment extremely challenging.
2. Immune Evasion: The bacteria can inhibit white blood cell attacks and dampen initial inflammatory responses, allowing it to establish infection more easily.
3. Antibiotic Resistance: Many strains have developed resistance to multiple antibiotics, including carbapenems. These carbapenem-resistant Enterobacteriaceae (CRE) strains are particularly dangerous in healthcare settings.
4. Capsular Polysaccharide: The thick polysaccharide capsule protects the bacteria from complement-mediated killing and phagocytosis.
5. Siderophore Production: Klebsiella produces high-affinity iron chelators that allow it to compete effectively for iron in the host environment, supporting its growth and virulence.

Klebsiella Pneumoniae Infections: Clinical Manifestations

Respiratory Infections

Klebsiella pneumoniae is best known for causing severe pneumonia, particularly in individuals with compromised immune systems. The infection typically affects middle-aged and older adults with underlying conditions such as:

• Alcoholism
• Diabetes mellitus
• Chronic obstructive pulmonary disease (COPD)
• Weakened immune systems

The hallmark of Klebsiella pneumonia is the production of thick, bloody, mucoid sputum often described as “currant jelly sputum.” The infection causes necrosis, inflammation, and hemorrhage within lung tissue, leading to destructive changes that can be life-threatening.

Healthcare-Associated Infections

In hospital settings, Klebsiella pneumoniae is a major cause of nosocomial (hospital-acquired) infections affecting:

• Urinary tract: Often associated with catheter use
• Bloodstream: Can lead to sepsis and septic shock
• Surgical wounds: Particularly in immunocompromised patients
• Lower respiratory tract: Especially in patients on mechanical ventilation

The presence of invasive devices, contaminated respiratory support equipment, and antibiotic use significantly increase the risk of Klebsiella infection in healthcare settings.

Other Clinical Syndromes

Klebsiella can cause a variety of other infections including:

• Liver abscesses
• Meningitis
• Cholecystitis (gallbladder infection)
• Osteomyelitis (bone infection)
• Skin and soft tissue infections
• Intra-abdominal infections

Klebsiella and Small Intestinal Bacterial Overgrowth (SIBO)

Recent research has established a strong connection between Klebsiella species and SIBO, a condition characterised by excessive bacterial growth in the small intestine that produces gastrointestinal symptoms.

The SIBO Connection: Groundbreaking Research

A landmark 2024 study published in Clinical Gastroenterology and Hepatology examined 483 patients and made several significant discoveries:

• Klebsiella and Escherichia/Shigella were found to be the dominant bacteria in SIBO
• Only a few specific E. coli and Klebsiella strains/species represented 40.24% of all duodenal bacteria in SIBO patients
• The relative abundance of Klebsiella progressively increased in patients with higher bacterial counts
• Klebsiella presence correlated significantly with abdominal pain, diarrhoea, and bloating severity

The study confirmed that a bacterial concentration of ≥10³ CFU/mL (colony-forming units per milliliter) is the optimal SIBO threshold, and this overgrowth is associated with:

• Significantly decreased microbial diversity
• Network disruption in the gut microbiome
• Enhanced hydrogen and hydrogen sulfide production
• Worsening gastrointestinal symptoms

Symptoms of Klebsiella-Associated SIBO

When Klebsiella overgrows in the small intestine, it can cause:

• Chronic bloating and abdominal distension
• Abdominal pain and cramping
• Diarrhoea or constipation (or alternating between both)
• Excessive gas and flatulence
• Malabsorption and nutritional deficiencies
• Fatigue and brain fog
• Food intolerances

Klebsiella, Leaky Gut, and Systemic Inflammation

As a gram-negative bacterium, Klebsiella pneumoniae plays a significant role in intestinal permeability (commonly called “leaky gut”) and systemic inflammation through its LPS endotoxin.

Discover the reasons for your gut symptoms.

View our gut health tests

The Inflammatory Cascade

Research has demonstrated that Klebsiella-mediated inflammation occurs through several mechanisms:

1. LPS-Induced Inflammation: When Klebsiella overgrows or crosses the intestinal barrier, its LPS activates the caspase-11 inflammasome in gut epithelial cells, leading to release of pro-inflammatory cytokines including IL-18, IL-6, IL-1β, and TNF-α.
2. Intestinal Barrier Disruption: A 2022 study found that Klebsiella presence in the gut increases intestinal permeability, allowing bacterial molecules (LPS and other toxins) to translocate into systemic circulation.
3. Pro-inflammatory Cytokine Production: Research published in 2022 showed that SIBO patients with elevated Klebsiella pneumoniae had significantly higher levels of IL-1β in duodenal fluid , and those with all three elevated cytokines (IL-1β, IL-6, TNF-α) had an odds ratio of 3.47 for having SIBO.
4. Mucosal Damage: Gram-negative bacteria like Klebsiella can produce toxins that directly damage the intestinal mucosa, interfering with absorptive function and causing secretory diarrhoea.

Consequences of Klebsiella-Induced Inflammation

The inflammatory response triggered by Klebsiella can contribute to:

• Inflammatory Bowel Disease (IBD): Studies have isolated Klebsiella strains from ulcerative colitis patients that induce and promote colitis
• Metabolic dysfunction: Systemic LPS exposure is associated with insulin resistance and metabolic syndrome
• Autoimmune conditions: Through molecular mimicry mechanisms (discussed below)
• Chronic fatigue and systemic symptoms: Due to ongoing low-grade inflammation

Klebsiella and Autoimmune Disease: The Ankylosing Spondylitis Connection

One of the most fascinating associations with Klebsiella pneumoniae is its suspected role in ankylosing spondylitis (AS), a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints.

The HLA-B27 and Klebsiella Link

Ankylosing spondylitis shows a striking association with the HLA-B27 genetic marker—over 90% of AS patients carry this antigen compared to only 6-8% of the general white population. Research has uncovered a compelling molecular mimicry mechanism:

Molecular Mimicry Explained:

Molecular mimicry is when a foreign invader (like a bacteria or virus) looks so similar to parts of your own body that your immune system gets confused and accidentally attacks both.Think of it like this: Imagine your immune system is a security guard who’s been trained to recognise and remove intruders wearing a specific uniform – say, a red jacket with white stripes. The problem is, some of your own cells happen to wear something that looks very similar. When the security guard spots the intruder and learns to attack anything with that pattern, it might also start attacking your own cells by mistake.

Clinical Evidence Supporting the Connection

Multiple studies have documented:

• 53% of Reiter’s syndrome patients and 29% of AS patients had antibodies to HLA-B27 peptides, compared to only 5% of healthy HLA-B27-positive controls
• Over 40% of HLA-B27-positive AS/Reiter’s syndrome patients had antibodies to Klebsiella proteins
• Increased frequency of Klebsiella in fecal cultures of AS patients during active disease phases
• Elevated anti-Klebsiella antibodies during disease flares

The Low-Starch Diet Hypothesis

Because Klebsiella thrives on starch, some researchers have proposed that reducing starch intake may benefit AS patients by limiting bacterial fuel sources. While this remains an area of active investigation, some clinicians recommend low-starch diets as part of comprehensive AS management.

Klebsiella and Inflammatory Bowel Disease

Beyond ankylosing spondylitis, Klebsiella pneumoniae has been implicated in inflammatory bowel diseases including ulcerative colitis and Crohn’s disease.

Mechanisms in IBD Pathogenesis

Research has shown that certain Klebsiella strains:

• Colonise the colon and directly induce colitis through caspase-11 activation
• Promote DSS-mediated colitis (an experimental model of IBD)
• Increase expression of cox-2, IL-1β, IL-6, and TNF-α in colonic tissue
• Activate the nuclear factor-κB inflammatory pathway

A 2023 study isolated a Klebsiella pneumoniae strain from ulcerative colitis patients that directly induced colitis and promoted experimentally-induced colitis.

Risk Factors for Klebsiella Overgrowth and Infection

Understanding who is at risk helps in prevention and early intervention:

Gut Microbiome Disruption

• Antibiotic use: Broad-spectrum antibiotics disrupt beneficial bacteria that normally keep Klebsiella in check
• Proton pump inhibitors (PPIs): Long-term use may alter stomach acid production, affecting bacterial balance
• Poor diet: High sugar and refined carbohydrate intake can promote pathogenic bacterial growth
• Chronic stress: Affects gut motility and immune function

Compromised Immune Function

• Diabetes mellitus
• HIV/AIDS or other immunodeficiency conditions
• Cancer and chemotherapy
• Organ transplantation and immunosuppressive medications
• Chronic alcoholism
• Advanced age

Gut Motility Disorders

• Scleroderma
• Diabetic gastroparesis
• Previous gastrointestinal surgery
• Medications affecting gut motility (opioids, anticholinergics)

Healthcare-Related Factors

• Hospitalisation, especially in intensive care units
• Mechanical ventilation
• Urinary catheterisation
• Invasive procedures
• Enteral nutrition without fiber

Natural Treatment Options: What Does the Research Say?

While conventional treatment often relies on antibiotics, growing antibiotic resistance has sparked interest in natural and complementary approaches. Recent research has explored various probiotic and prebiotic strategies.

Probiotics: Evidence-Based Options

Lactobacillus Species

Multiple studies have demonstrated that specific Lactobacillus strains can inhibit Klebsiella pneumoniae:

2022 Egyptian Study:

• Examined cell-free supernatant from Lactobacillus strains against multidrug-resistant Klebsiella pneumoniae
• L. helveticus and L. rhamnosus showed significant antibacterial activity
• The lower pH produced by Lactobacillus cultures contributed to inhibitory effects

Lactobacillus species with Anti-Klebsiella Activity:

• L. rhamnosus
• L. helveticus
• L. plantarum
• L. acidophilus
• L. animalis
• L. fermentum

These probiotics work through multiple mechanisms:

• Production of organic acids (lactic acid, acetic acid) that lower pH
• Secretion of bacteriocins (antimicrobial peptides)
• Competition for nutrients and adhesion sites
• Immune system modulation

Recommended Products: Advanced Daily Biotic, Ideal Bowel Support, Advanced Acidophilus

I am not suggesting trying all of them at once, but they all include researched species (those listed above). As research develops we may discover specific strains that are most effective too.

Saccharomyces boulardii

This beneficial yeast has shown particular promise:

• Helps discourage Klebsiella growth
• Reduces intestinal inflammation
• Boosts immune function
• Improves digestion
• Commonly recommended for SIBO patients

Recommended product: Saccharomyces Boulardii

Bifidobacterium Species

A 2015 study found that Bifidobacterium longum 51A:

• Provided protection against Klebsiella pneumoniae lung infection in mice
• Induced faster resolution of inflammation
• Increased IL-10 (anti-inflammatory cytokine) production
• Decreased lung damage and bacterial burden
• Resulted in 100% survival versus 50% in untreated mice

Unfortunately this strain isn’t commercially available yet.

Multi-Strain Probiotic Combinations

A 2024 study showed that combining Lactobacillus rhamnosus, Lactobacillus sake, and Bacillus subtilis (ratio 5:5:1):

• Significantly inhibited K. pneumoniae biofilm formation
• Down-regulated biofilm-related genes
• Blocked Klebsiella adhesion to intestinal cells
• Reduced pro-inflammatory cytokine expression

Recommended product: Essential Biotic and Bacillus subtilis

Prebiotics: Feeding the Good Bacteria

Prebiotics are non-digestible fibers that selectively promote beneficial bacteria growth:

Research-Supported Prebiotics

Fructo-oligosaccharides (FOS) and Galacto-oligosaccharides (GOS):

• A 2023 study in formula-fed infants showed synbiotic feeding (prebiotics + L. paracasei F19) resulted in:
  • Lower abundance of Klebsiella
  • Higher abundance of beneficial Bifidobacterium breve
  • Increased anti-microbial metabolites
  • Reduced respiratory infections

Recommended Product: FOS and GOS

Lactulose and Isomalto-oligosaccharides:

• A 2022 study demonstrated that Lactobacillus combined with these prebiotics effectively inhibited KPC-2-producing K. pneumoniae colonisation
• Synbiotic (probiotic + prebiotic) combinations showed superior effects

Dietary Fiber:

• A 2024 study published in the Journal of Clinical Investigation found that dietary fiber reduced dissemination of Klebsiella pneumoniae
• Fiber promoted colonisation resistance through supporting beneficial microbiota

Recommended Product: Psyllium Husk

Important Prebiotic Caution for SIBO

For individuals with SIBO, high-FODMAP prebiotics (garlic, onions, asparagus, Jerusalem artichokes) may initially worsen symptoms. It’s essential to work with a healthcare provider to introduce prebiotics gradually.

Fecal Microbiota Transplantation (FMT)

Emerging research suggests FMT may be beneficial:

A 2024 study on K. pneumoniae-induced sepsis in mice found:

• FMT improved intestinal flora structure
• Increased beneficial metabolites (fatty acids, secondary bile acids)
• Reduced systemic inflammation
• Repaired alveolar epithelial barrier function
• Combination of antibiotics + FMT was superior to antibiotics alone
• FMT reduced antibiotic-induced dysbiosis and antibiotic resistance gene selection

Dietary Modifications

Low-Starch Diet:

• Particularly important for AS patients
• Reduces fuel source for Klebsiella
• May help “starve out” overgrowth

Avoid Refined Carbohydrates and Sugars:

• Contribute to gut dysbiosis
• Provide energy for pathogenic bacteria

Anti-Inflammatory Diet:

• Focus on whole foods, vegetables, fruits
• Omega-3 fatty acids from fish or supplements
• Polyphenol-rich foods (berries, green tea, olive oil)

Herbal Antimicrobials

While specific research on herbs is limited, clinical practitioners report success with:

• Berberine-containing herbs (goldenseal, Oregon grape)
• Oregano oil
• Garlic extract
• Neem
• Pau d’arco

These should be used under professional guidance, as part of a comprehensive treatment protocol.

Immune Support

Key Nutrients:

• Vitamin A: Essential for immune cell function and mucosal barrier integrity
• Vitamin D: Modulates immune response and has antimicrobial properties
• Selenium: Supports immune cell activity and reduces inflammation
• Zinc: Critical for immune function and gut barrier integrity

Testing for Klebsiella Overgrowth

Stool Testing

Comprehensive stool analysis like our Ultimate Gut Health Test can:

• Identify presence and abundance of Klebsiella
• Assess overall microbiome balance
• Detect other gut imbalances

SIBO Breath Testing

For suspected SIBO:

• Hydrogen and methane breath testing can diagnose bacterial overgrowth
• Does not identify specific bacterial species
• Results guide treatment approach

Duodenal Aspiration

• Gold standard for SIBO diagnosis
• Allows direct culture and identification of bacteria
• Rarely used in routine practice due to invasiveness

Conventional Medical Treatment

Antibiotic Therapy

Traditional treatment includes:

• Respiratory infections: Third-generation cephalosporins, fluoroquinolones, carbapenems
• Urinary tract infections: Fluoroquinolones, aminoglycosides
• SIBO: Rifaximin, neomycin, metronidazole

Challenges:

• Increasing antibiotic resistance
• Destruction of beneficial gut bacteria
• Risk of recurrence after treatment
• Potential for selecting resistant strains

Prevention Strategies

Maintaining Gut Health

1. Probiotic-rich foods: Yogurt, kefir, sauerkraut, kimchi
2. Prebiotic fiber: Vegetables, fruits, whole grains (if tolerated)
3. Diverse diet: Promotes microbiome diversity
4. Adequate hydration: Supports gut motility and function
5. Stress management: Yoga, meditation, adequate sleep

Antibiotic Stewardship

• Use antibiotics only when necessary
• Complete prescribed courses appropriately
• Consider probiotic supplementation during and after antibiotic treatment
• Avoid unnecessary antibiotic use in agriculture

Infection Prevention

In healthcare settings:

• Hand hygiene compliance
• Appropriate isolation precautions
• Environmental cleaning
• Catheter care protocols

The Future: Emerging Research and Treatment Approaches

Research continues to explore:

• Bacteriophage therapy: Viruses that specifically target Klebsiella
• Immunotherapy: Vaccines and monoclonal antibodies
• Microbiome restoration: Advanced FMT protocols
• Personalised medicine: Tailoring treatment based on strain characteristics
• Novel antibiotics: Drugs targeting carbapenem-resistant strains
• Gut-lung axis interventions: Addressing systemic effects through gut health

Conclusion

Klebsiella, particularly K. pneumoniae, represents a significant health challenge in the modern era. While it can exist as a harmless commensal organism in a balanced gut microbiome, overgrowth and infection can lead to serious consequences ranging from respiratory infections to SIBO, inflammatory bowel disease, and even autoimmune conditions like ankylosing spondylitis.

The gram-negative nature of Klebsiella means its LPS endotoxin can trigger profound inflammatory responses, contributing to intestinal permeability (leaky gut) and systemic inflammation. This makes addressing Klebsiella overgrowth crucial not just for gastrointestinal health, but for overall wellbeing.

Emerging research on natural treatment options—particularly probiotics like Lactobacillus and Bifidobacterium species, targeted prebiotics, and dietary modifications—offers hope for managing an overgrowth while supporting overall microbiome health. These approaches may be particularly valuable given the growing challenge of antibiotic resistance.

If you suspect Klebsiella overgrowth or SIBO, work with a qualified healthcare provider who can order appropriate testing and develop a comprehensive treatment plan tailored to your individual needs. A multifaceted approach addressing diet, microbiome support, immune function, and underlying risk factors offers the best chance for long-term success.

---

References

1. Leite et al. Defining Small Intestinal Bacterial Overgrowth by Culture and High Throughput Sequencing. Clin Gastroenterol Hepatol. 2024;22(2):259-270. (click here)
2. Koren et al. Small Intestine Bacterial Overgrowth Can Form an Indigenous Proinflammatory Environment in the Duodenum: A Prospective Study. PMC. (click here)
3. Lipopolysaccharide. StatPearls. Updated April 17, 2023. (click here)
4. Tang et al. The effect of Lactobacillus with prebiotics on KPC-2-producing Klebsiella pneumoniae. Front Microbiol. 2022;13:1050247. (click here)
5. Tang et al., Gut microbes improve prognosis of K. pneumoniae pulmonary infection through the lung-gut axis. Front Cell Infect Microbiol. 2024;14:1392376. (click here)
6. Zhou et al. Klebsiella pneumoniae Induces Inflammatory Bowel Disease Through Caspase-11–Mediated IL18 in the Gut Epithelial Cells. PMC. (click here)
7. Ghaith et al., In vitro antibacterial effect of probiotics against Carbapenamase-producing multidrug-resistant Klebsiella pneumoniae clinical isolates, Cairo, Egypt. J Egypt Public Health Assoc. 2022;97:19. (click here)
8. Schwimmbeck et al., Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter’s syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med. 1987;166(1):173-81. (click here)
9. Ebringer A, Rashid T. Ankylosing spondylitis is linked to Klebsiella—the evidence. Clin Rheumatol. 2007;26(6):858-64. (click here)
10. Zhang et al., The inhibition mechanism of co-cultured probiotics on biofilm formation of Klebsiella pneumoniae. J Appl Microbiol. 2024;135(6):lxae138. (click here)
11. Stensvold et al. Targeting the gut-lung axis by synbiotic feeding to infants in a randomized controlled trial. BMC Biol. 2023;21:38. (click here)
12. Dubreuil et al., Control of Klebsiella pneumoniae pulmonary infection and immunomodulation by oral treatment with the commensal probiotic Bifidobacterium longum 51A. Microbes Infect. 2016;18(3):180-9. (click here)
13. Hecht et al. Dietary carbohydrates regulate intestinal colonization and dissemination of Klebsiella pneumoniae. JCI. 2024;174726. (click here)
14. Riwes M, Reddy P. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis. 2013. (click here)
15. Khoshbin K, Camilleri M. Small Intestinal Bacterial Overgrowth: A Comprehensive Review. PMC. (click here)
16. Wattanakul et al. A review: Virulence factors of Klebsiella pneumonia as emerging infection on the food chain. PMC. 2022. (click here)
17. Klebsiella Infections: Background, Pathophysiology, Epidemiology. Medscape. (click here)
18. Mohr et al. Lipopolysaccharide and the gut microbiota: considering structural variation. FEBS Lett. 2022;596(7):849-875. (click here)
19. Wangchuk P, Pyne SG. Certainties and uncertainties of SIBO. Gut Microbiota for Health. October 26, 2023. (click here)